Correction: Research progress of B7-H3 in malignant tumors

Shuaixiang Zhao^#^{1

2}, He Zhang^#¹, Guanning Shang^{1

2}

Affiliations

¹ Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
² The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.

^# Contributed equally.

Published Erratum

Shuaixiang Zhao et al. Front Immunol. 2025.

. 2025 Jun 17:16:1641733.

doi: 10.3389/fimmu.2025.1641733. eCollection 2025.

Shuaixiang Zhao^#^{1

2}, He Zhang^#¹, Guanning Shang^{1

2}

¹ Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
² The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1586759.].

Keywords: B7-H3(CD276); drug trials; immunity; malignant tumor; targeted therapy.

Research progress of B7-H3 in malignant tumors.
Zhao S, Zhang H, Shang G. Zhao S, et al. Front Immunol. 2025 May 30;16:1586759. doi: 10.3389/fimmu.2025.1586759. eCollection 2025. Front Immunol. 2025. PMID: 40519928 Free PMC article. Review.